Published in Trends Cancer on June 27, 2016
MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clin Cancer Res (2017) 0.76
Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer (2017) 0.75
Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis. PLoS One (2017) 0.75
GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. Oncotarget (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
On the origin of cancer cells. Science (1956) 49.55
TOR signaling in growth and metabolism. Cell (2006) 35.29
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 13.49
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
MYC on the path to cancer. Cell (2012) 8.65
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A (2003) 8.20
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 8.07
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell (2005) 7.65
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Glycolysis inhibition for anticancer treatment. Oncogene (2006) 6.55
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 5.43
Localization of the primary metabolic block produced by 2-deoxyglucose. J Biol Chem (1957) 4.79
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature (2013) 4.71
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem (2002) 3.50
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 3.31
The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer (2005) 2.82
Regulation of mTORC1 by amino acids. Trends Cell Biol (2014) 2.64
Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene (2006) 2.57
Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science (1984) 2.46
Metabolic flux and the regulation of mammalian cell growth. Cell Metab (2011) 2.27
Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem (2011) 2.24
Implications of NRAS mutations in AML: a study of 2502 patients. Blood (2006) 2.20
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell (2015) 2.13
mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature (2014) 2.13
Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol Cell Biol (2011) 2.11
Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun (1990) 2.06
Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res (2006) 2.03
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A (2012) 2.02
Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A (1988) 2.01
Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle (2008) 1.98
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer (2004) 1.78
Serine and glycine metabolism in cancer. Trends Biochem Sci (2014) 1.70
Targeting glucose metabolism for cancer therapy. J Exp Med (2012) 1.64
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle (2010) 1.42
Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 1.34
Metformin in cancer treatment and prevention. Annu Rev Med (2014) 1.23
Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity. J Biol Chem (1991) 1.21
Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab (2012) 1.21
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. Int J Cell Biol (2012) 1.17
Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res (1995) 1.15
Targeting AMPK for cancer prevention and treatment. Oncotarget (2015) 1.13
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
Ceramide signaling in apoptosis. Br Med Bull (1997) 1.10
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol (2015) 1.08
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A (2015) 1.07
Distribution of the glucose transporters in human brain tumors. Cancer Res (1992) 1.03
Supercompetitor status of Drosophila Myc cells requires p53 as a fitness sensor to reprogram metabolism and promote viability. Cell Metab (2014) 1.03
Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts. J Biol Chem (1988) 1.02
Heparan sulfate signaling in cancer. Trends Biochem Sci (2014) 0.97
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs (2012) 0.93
Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding. Biochim Biophys Acta (2004) 0.90
Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer (2013) 0.88
c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. J Biol Chem (2014) 0.88
Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress. Mol Oncol (2014) 0.87
Cellular targets for activation by c-Myc include the DNA metabolism enzyme thymidine kinase. DNA Cell Biol (1997) 0.85
Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma. Surgery (1990) 0.84
Cancer cell metabolism regulates extracellular matrix degradation by invadopodia. Eur J Cell Biol (2013) 0.84
Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase. Int J Hematol (1997) 0.83
Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells. Cell Death Differ (2014) 0.82
A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer (2003) 0.79
Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma. Hepatology (1990) 0.79
N-myc oncogene amplification and catecholamine metabolism in children with neuroblastoma. Lancet (1987) 0.79
Metformin for cancer prevention. Front Med (2011) 0.78
Polyamine metabolism and interconversion in NIH 3T3 and ras-transfected NIH 3T3 cells. Cancer Res (1988) 0.77
N-myc oncogene amplification and catecholamine metabolism in patients with neuroblastoma. Lancet (1987) 0.76
Addicted to AA (Acetoacetate): A Point of Convergence between Metabolism and BRAF Signaling. Mol Cell (2015) 0.76
Signal transduction in EJ-H-ras-transformed cells: de novo synthesis of diacylglycerol and subversion of agonist-stimulated inositol lipid metabolism. FEBS Lett (1989) 0.75